State of Alaska Department of Revenue’s BioMarin Pharmaceuticals BMRN Stock Holding History

State of Alaska Department of Revenue’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.08M	Sell	18,939 -322	-2%	-$17.6K	0.01%	1009
2026 Q1	$1.09M	Hold	19,261	–	–	0.01%	1032
2025 Q4	$1.14M	Sell	19,261 -1,730	-8%	-$94.2K	0.01%	1001
2025 Q3	$1.14M	Sell	20,991 -574	-3%	-$32.8K	0.01%	1002
2025 Q2	$1.19M	Sell	21,565 -770	-3%	-$45.3K	0.01%	961
2025 Q1	$1.58M	Buy	22,335 +605	+3%	+$40.7K	0.02%	791
2024 Q4	$1.43M	Sell	21,730 -7,495	-26%	-$502K	0.02%	871
2024 Q3	$2.05M	Sell	29,225 -7,045	-19%	-$589K	0.02%	704
2024 Q2	$2.98M	Buy	36,270 +15,175	+72%	+$1.26M	0.03%	536
2024 Q1	$1.84M	Sell	21,095 -6,870	-25%	-$615K	0.02%	729
2023 Q4	$2.7M	Buy	27,965 +360	+1%	+$31.8K	0.03%	566
2023 Q3	$2.44M	Buy	27,605 +865	+3%	+$77K	0.03%	565
2023 Q2	$2.32M	Buy	26,740 +22,505	+531%	+$2.12M	0.03%	608
2023 Q1	$411K	Hold	4,235	–	–	﹤0.01%	1450
2022 Q4	$438K	Sell	4,235 -250	-6%	-$23.5K	0.01%	1402
2022 Q3	$380K	Sell	4,485 -670	-13%	-$59.7K	0.01%	1438
2022 Q2	$427K	Buy	+5,155	New	+$410K	0.01%	1416
2020 Q3	–	Sell	-86,641	Closed	-$10.7M	–	1639
2020 Q2	$10.7M	Buy	+86,641	New	+$8.61M	0.14%	183
2019 Q3	–	Sell	-20,677	Closed	-$1.77M	–	1649
2019 Q2	$1.77M	Buy	20,677 +77	+0.4%	+$6.59K	0.03%	559
2019 Q1	$1.83M	Sell	20,600 -1,207	-6%	-$112K	0.03%	544
2018 Q4	$1.86M	Buy	21,807 +175	+0.8%	+$16.6K	0.04%	514
2018 Q3	$2.1M	Buy	21,632 +342	+2%	+$34.1K	0.04%	524
2018 Q2	$2M	Sell	21,290 -541	-2%	-$47.4K	0.04%	531
2018 Q1	$1.77M	Buy	21,831 +3,140	+17%	+$269K	0.04%	541
2017 Q4	$1.67M	Buy	18,691 +13,080	+233%	+$1.14M	0.04%	528
2017 Q3	$522K	Buy	5,611 +1,860	+50%	+$164K	0.03%	682
2017 Q2	$340K	Buy	3,751 +350	+10%	+$31.8K	0.02%	584
2017 Q1	$298K	Buy	+3,401	New	+$303K	0.02%	498

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

DnB Asset Management Oslo, Norway $35.7B AUM 27.58% 1-Year Est. Return

State of Alaska Department of Revenue's BMRN Position: Q2 2026 in Review

State of Alaska Department of Revenue reduced its BioMarin Pharmaceuticals (BMRN) stake by 1.7% in Q2 2026, selling an estimated $17.6K and leaving 18,939 shares worth $1.08M. The position accounts for 0.01% of the portfolio, ranked #1009.

State of Alaska Department of Revenue first reported a position in BMRN in Q1 2017 and has held it in 28 quarters since. The position peaked at $10.7M in Q2 2020. 356 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

State of Alaska Department of Revenue held 18,939 shares of BioMarin Pharmaceuticals worth $1.08M as of Q2 2026.
State of Alaska Department of Revenue sold 322 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $17.6K.
BioMarin Pharmaceuticals made up 0.01% of State of Alaska Department of Revenue's portfolio in Q2 2026, its #1009 holding.
State of Alaska Department of Revenue first reported a position in BioMarin Pharmaceuticals in Q1 2017 and has held it in 28 quarters since.
State of Alaska Department of Revenue's BioMarin Pharmaceuticals position peaked at $10.7M in Q2 2020.
356 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on State of Alaska Department of Revenue's 13F filing for Q2 2026, filed 20 Jul 2026.